Huahai Pharmaceutical approves use of idle funds

Zhejiang Huahai Pharmaceutical Co., Ltd. (SSE:600521) announced that its 8th Supervisory Committee's 21st extraordinary meeting, held on May 21, 2025, has approved the temporary use of idle raised funds to supplement working capital. The decision was made with a unanimous vote of 3-0-0. The company plans to use no more than CNY 1.81 billion of idle funds for this purpose. To standardize the management of these funds and protect investor interests, the company will open dedicated accounts for the raised funds, sign tripartite agreements with the sponsor and the depositary bank, and implement fund storage supervision in accordance with regulatory guidelines, including those from the Shanghai Stock Exchange.